Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab plus focal laser versus ranibizumab monotherapy in non-responders with diabetic macular edema
jRCTs061180035Completed
- Sponsor
- Novartis
- Start
- Jan 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Novartis. Primary endpoint: Change in best corrected visual acuity (BCVA) at 6 months. Started Jan 2017; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCTs061180035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180035.